European Rare Blood Disorders Platform (ENROL)
Recruiting
Observational Study
Anemia
Bone Marrow Failure
Bleeding Disorder
Iron Metabolism Disorders
Myeloma
Lymphoid Neoplasm
Myeloma, Malignant
Leukemia
Anemia, Sickle Cell
Thalassemia
Blood Cancer
Red Cell Membrane and Enzyme Abnormalities
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- Up to 100
- Sex
- Any
- Study type
- Observational
- Participants needed
- 37,090 (estimated)
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
ENROL, the European Rare Blood Disorders Platform has been conceived in the core of ERN-EuroBloodNet as an umbrella for both new and already existing registries on Rare Hematological Diseases (RHDs). ENROL aims at avoiding fragmentation of data by promoting the standards for patient registries' interoperability released by the EU RD platform.
ENROL's principle is to maximize public benefit from d…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients must meet all of the following criteria to be included in the ENROL Registry
* Age from 0-100, both female and male
* Diagnosed as RHDs according to ORPHANET classification
* Able and willing to provide written informed consent (patient or legal representative for min…
Contacts